CN113197313B - Probiotic composition with effects of improving insulin resistance and fasting blood glucose and preparation method thereof - Google Patents
Probiotic composition with effects of improving insulin resistance and fasting blood glucose and preparation method thereof Download PDFInfo
- Publication number
- CN113197313B CN113197313B CN202010911082.0A CN202010911082A CN113197313B CN 113197313 B CN113197313 B CN 113197313B CN 202010911082 A CN202010911082 A CN 202010911082A CN 113197313 B CN113197313 B CN 113197313B
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- bifidobacterium
- probiotic composition
- insulin resistance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 95
- 239000006041 probiotic Substances 0.000 title claims abstract description 66
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 66
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 63
- 239000008103 glucose Substances 0.000 title claims abstract description 63
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 62
- 206010022489 Insulin Resistance Diseases 0.000 title claims abstract description 50
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 50
- 210000004369 blood Anatomy 0.000 title claims abstract description 46
- 239000008280 blood Substances 0.000 title claims abstract description 46
- 230000000694 effects Effects 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 43
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 39
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims abstract description 23
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 19
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 19
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 8
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 8
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 8
- 241000186660 Lactobacillus Species 0.000 claims abstract description 6
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 86
- 239000000463 material Substances 0.000 claims description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 32
- 238000002156 mixing Methods 0.000 claims description 26
- 230000001580 bacterial effect Effects 0.000 claims description 21
- 229920001353 Dextrin Polymers 0.000 claims description 19
- 239000004375 Dextrin Substances 0.000 claims description 19
- 235000019425 dextrin Nutrition 0.000 claims description 19
- 238000005303 weighing Methods 0.000 claims description 18
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 16
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 16
- 239000000377 silicon dioxide Substances 0.000 claims description 16
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 claims description 15
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 15
- 235000000832 Ayote Nutrition 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 13
- 235000009854 Cucurbita moschata Nutrition 0.000 claims description 13
- 240000001980 Cucurbita pepo Species 0.000 claims description 13
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 13
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 13
- 235000015136 pumpkin Nutrition 0.000 claims description 13
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 13
- 229920001202 Inulin Polymers 0.000 claims description 12
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 12
- 229940029339 inulin Drugs 0.000 claims description 12
- 235000012239 silicon dioxide Nutrition 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 241000186000 Bifidobacterium Species 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 4
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 3
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008267 milk Substances 0.000 claims 2
- 210000004080 milk Anatomy 0.000 claims 2
- 235000013336 milk Nutrition 0.000 claims 2
- 230000001603 reducing effect Effects 0.000 abstract description 12
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 206010056997 Impaired fasting glucose Diseases 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940068140 lactobacillus bifidus Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 208000013527 cardiovascular neoplasm Diseases 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Abstract
The invention relates to the field of functional foods, in particular to a probiotic composition with the functions of improving insulin resistance and fasting blood glucose and a preparation method thereof, wherein the probiotic composition with the functions of improving insulin resistance and fasting blood glucose comprises the following components: bifidobacterium lactis (Bifidobacterium lactis) MN-Gup, lactobacillus acidophilus (Lactobacillus acidophilus) NCFM, bifidobacterium lactis (Bifidobacterium lactis) B420, bifidobacterium adolescentis (Bifidobacterium adolescentis) BA02 and lactobacillus reuteri (Lactobacillus ruteri) SD5865; the probiotics in the probiotic composition cooperatively play roles of reducing insulin resistance index and reducing fasting blood glucose.
Description
Technical Field
The invention relates to the field of functional foods, in particular to a probiotic composition with the functions of improving insulin resistance and fasting blood glucose and a preparation method thereof.
Background
Diabetes mellitus is a group of metabolic diseases characterized by an elevated level of chronic blood glucose (abbreviated as blood glucose), the prevalence of which increases rapidly with the increasing level of living of people, and changes in lifestyle have become the third most non-infectious disease after cardiovascular disease and tumor in developed countries, which can cause multiple system damage, cause chronic progressive changes in tissues such as eyes, kidneys, nerves, heart and blood vessels, cause functional defects and failure, and seriously threaten human health. Diabetes mellitus is classified into type 1 diabetes, type 2diabetes, gestational diabetes and other types of diabetes, depending on the cause of the disease. Type 2diabetes (t 2 dm), among others, refers to a metabolic disorder characterized by hyperglycemia caused by insulin resistance-induced destruction of islet beta cells or relative lack of insulin, and is the largest number of one subtype of diabetes.
Insulin resistance and insulin β cell secretion defects are important pathophysiological changes in the pathogenesis of T2 DM. Impaired Fasting Glucose (IFG) belongs to an intermediate state between normal glucose metabolism and diabetes, known as pre-diabetes. Any diabetic patient may go through the IFG stage during the course of the onset. Therefore, improving insulin resistance and fasting blood glucose is very important for alleviating diabetes, especially T2 DM. Therefore, the invention provides a probiotic composition with the functions of improving insulin resistance and fasting blood glucose and a preparation method thereof.
Disclosure of Invention
Therefore, the technical problem to be solved by the invention is to provide a probiotic composition with the functions of improving insulin resistance and fasting blood glucose and a preparation method thereof.
For this purpose, the invention provides the following technical scheme:
a probiotic composition having improved insulin resistance and fasting glucose comprising: bifidobacterium lactis (Bifidobacterium lactis) MN-Gup, lactobacillus acidophilus (Lactobacillus acidophilus) NCFM, bifidobacterium lactis (Bifidobacterium lactis) B420, bifidobacterium adolescentis (Bifidobacterium adolescentis) BA02 and lactobacillus reuteri (Lactobacillus ruteri) SD5865.
Further, the weight portions are as follows:
1-50 parts of bifidobacterium lactis MN-Gup bacterial powder;
1-50 parts of lactobacillus acidophilus NCFM powder;
0.1-20 parts of bifidobacterium lactis B420 powder;
1-50 parts of bifidobacterium adolescentis BA02 bacteria powder; and
0.1-30 parts of lactobacillus reuteri SD5865 bacterial powder.
Further, the food additive also comprises food raw materials and/or food or medical acceptable auxiliary materials or additives.
Further, the food material is at least one selected from stachyose, inulin, fructo-oligosaccharide, pumpkin powder and resistant dextrin, for enhancing proliferation and efficacy effects of the probiotics.
Further, the auxiliary materials or additives comprise silicon dioxide, and are used for improving the flowability of the formula.
Further, the probiotic composition further comprises the following components in parts by weight:
stachyose, 0-100 parts;
inulin, 0-80 parts;
0-80 parts of fructo-oligosaccharide;
0-50 parts of pumpkin powder;
0-100 parts of resistant dextrin;
silica, 0-10 parts.
Further, the probiotic composition comprises the following components in parts by weight:
1-5 parts of bifidobacterium lactis MN-Gup bacterial powder;
1-5 parts of lactobacillus acidophilus NCFM powder;
0.5-2 parts of bifidobacterium lactis B420 powder;
1-5 parts of bifidobacterium adolescentis BA02 bacteria powder;
1-3 parts of lactobacillus reuteri SD5865 bacteria powder;
stachyose 30-60 parts;
30-60 parts of inulin;
10-30 parts of fructo-oligosaccharide;
10-20 parts of pumpkin powder;
30-80 parts of resistant dextrin; and
silica, 0.2-1 part.
A method for preparing a probiotic composition with the functions of improving insulin resistance and fasting blood glucose comprises the steps of weighing selected components according to the selected weight portions, and then uniformly mixing.
Further, in the preparation method, the selected food raw materials and/or auxiliary materials or additives are weighed according to the selected weight portions and mixed uniformly;
weighing all the bacterial powders according to the selected weight portions and uniformly mixing to obtain a bacterial powder mixture;
mixing the above mixture of food materials and/or adjuvants or additives with the fungus powder mixture.
Further, in the preparation method, inulin and pumpkin powder are weighed and uniformly mixed and recorded as a material A;
respectively weighing stachyose, fructo-oligosaccharide, partial resistant dextrin and silicon dioxide for standby;
weighing stachyose and mixing with part of resistant dextrin, and uniformly mixing to obtain material B;
respectively weighing fructo-oligosaccharide and silicon dioxide for later use;
weighing the rest of resistant dextrin, lactobacillus MN-Gup, lactobacillus acidophilus NCFM, lactobacillus B420, bifidobacterium adolescentis BA02 and lactobacillus reuteri SD5865 powder, mixing uniformly and marking as a material C;
and uniformly mixing the material A, the material B, the material C, fructo-oligosaccharide and silicon dioxide.
The technical scheme of the invention has the following advantages:
1. the invention provides a probiotic composition for improving insulin resistance and fasting blood glucose, which comprises the following components: bifidobacterium lactis (Bifidobacterium lactis) MN-Gup, lactobacillus acidophilus (Lactobacillus acidophilus) NCFM, bifidobacterium lactis (Bifidobacterium lactis) B420, bifidobacterium adolescentis (Bifidobacterium adolescentis) BA02 and lactobacillus reuteri (Lactobacillus ruteri) SD5865; the applicant finds that compared with normal people, bifidobacteria in the intestinal tracts of adult diabetics are obviously fewer, and particularly the bifidobacteria of adolescents are obvious; the invention relates to a method for reducing harmful bacteria and endotoxin in human bodies, restoring barrier effect of intestinal walls, relieving inflammatory reaction, further restoring normal action of insulin, achieving the effects of reducing insulin resistance index and reducing fasting blood glucose, and further relieving diabetes.
2. The invention provides a probiotic composition for improving insulin resistance and fasting blood glucose, which comprises the following components: the weight portions are as follows: 1-50 parts of bifidobacterium lactis MN-Gup bacterial powder; 1-50 parts of lactobacillus acidophilus NCFM powder; 0.1-20 parts of bifidobacterium lactis B420 powder; 1-50 parts of bifidobacterium adolescentis BA02 bacteria powder; and 0.1-30 parts of lactobacillus reuteri SD5865 bacteria powder; in the proportion, the bifidobacterium lactis MN-Gup, the lactobacillus acidophilus NCFM, the bifidobacterium lactis B420, the bifidobacterium adolescentis BA02 and the lactobacillus reuteri SD5865 have strong synergistic effect, and the effects of reducing insulin resistance index and reducing fasting blood glucose are more remarkable.
3. The probiotic composition with the functions of improving insulin resistance and fasting blood glucose provided by the invention further comprises food raw materials, wherein the food raw materials are at least one selected from stachyose, inulin, fructo-oligosaccharide, pumpkin powder and resistant dextrin, and the food raw materials can promote proliferation of bifidobacterium lactis MN-Gup, lactobacillus acidophilus NCFM, bifidobacterium lactis B420, bifidobacterium adolescentis BA02 and lactobacillus reuteri SD5865 on one hand and can have a certain auxiliary effect on blood glucose and insulin reaction on the other hand.
4. The invention provides a probiotic composition for improving insulin resistance and fasting blood glucose, which comprises the following components in parts by weight: 1-5 parts of bifidobacterium lactis MN-Gup bacterial powder; 1-5 parts of lactobacillus acidophilus NCFM powder; 0.5-2 parts of bifidobacterium lactis B420 powder; 1-5 parts of bifidobacterium adolescentis BA02 bacteria powder; 1-3 parts of lactobacillus reuteri SD5865 bacteria powder; stachyose 30-60 parts; 30-60 parts of inulin; 10-30 parts of fructo-oligosaccharide; 10-20 parts of pumpkin powder; 30-80 parts of resistant dextrin; and 0.2 to 1 part of silicon dioxide; the composition has proper proportion, can directly depend on the effect of 5 probiotics in intestinal tracts, reduces in-vivo inflammation, improves insulin sensitivity and promotes blood sugar metabolism, thereby reducing fasting blood sugar and achieving the effect of assisting in reducing blood sugar.
5. According to the preparation method of the probiotic composition for improving insulin resistance and fasting blood glucose, provided by the invention, as the water content of pumpkin powder is high, inulin with a relatively high formula and a relatively low water content is selected to be mixed with the pumpkin powder, and the mixture is uniformly recorded as material A; mixing stachyose with higher water content with part of resistant dextrin, and uniformly mixing to obtain material B; the rest fructo-oligosaccharides and silicon dioxide with lower water content are respectively weighed for standby; because the weight of the bacterial powder is very light, the rest of resistant dextrin is required to be weighed and mixed with the bacterial powder of the bifidobacterium lactis MN-Gup, the lactobacillus acidophilus NCFM, the bifidobacterium lactis B420, the bifidobacterium adolescentis BA02 and the lactobacillus reuteri SD5865, so that the mixing uniformity of the formula is improved, and the evenly mixed premix is marked as a C material; and uniformly mixing the material A, the material B, the material C, fructo-oligosaccharide and silicon dioxide.
Detailed Description
The following examples are provided for a better understanding of the present invention and are not limited to the preferred embodiments described herein, but are not intended to limit the scope of the invention, any product which is the same or similar to the present invention, whether in light of the present teachings or in combination with other prior art features, falls within the scope of the present invention.
The specific experimental procedures or conditions are not noted in the examples and may be followed by the operations or conditions of conventional experimental procedures described in the literature in this field. The reagents or apparatus used were conventional reagent products commercially available without the manufacturer's knowledge.
The bifidobacterium lactis MN-Gup bacterial powder in the following examples is prepared according to a conventional method, and the method can be as follows:
and (3) taking a seed freezing tube of bifidobacterium lactis MN-Gup, activating and continuously activating the seed freezing tube in a culture medium of MRS+0.05% L-cysteine hydrochloride for three generations at 37 ℃, inoculating a starter to a fermentation tank containing the culture medium of MRS+0.05% L-cysteine hydrochloride for fermentation, centrifuging the seed freezing tube by a disc centrifuge after fermentation is finished, collecting thalli, mixing the thalli with a protective agent containing trehalose, emulsifying the mixture, freeze-drying the mixture in a freeze-drying machine, and crushing the mixture to finally obtain bacterial powder, wherein the viable count of the bacterial powder is more than or equal to 5000 hundred million CFU/g.
The lactobacillus acidophilus NCFM powder, the bifidobacterium lactis B420 powder, the bifidobacterium adolescentis BA02 powder and the lactobacillus reuteri SD5865 powder, the lactobacillus plantarum powder, the food raw materials and the auxiliary materials or the additives are all commercial products.
The animal bifidobacterium subspecies (Bifidobacterium animalis subsp.lactis) Mn-Gup are preserved in China general microbiological culture Collection center (CGMCC) No.15578, and the preservation date is 2018, 4 months and 10 days. In the present invention, bifidobacterium animalis subspecies (Bifidobacterium animalis subsp.lacti) MN-Gup, abbreviated as bifidobacterium lactis MN-Gup.
Lactobacillus acidophilus NCFM powder (viable count is greater than or equal to 2000 hundred million CFU/g), bifidobacterium lactis B420 powder (viable count is greater than or equal to 4000 hundred million CFU/g), bifidobacterium adolescentis BA02 powder (viable count is greater than or equal to 1000 hundred million CFU/g) and Lactobacillus reuteri SD5865 powder (viable count is greater than or equal to 3500 hundred million CFU/g), all of which are purchased from DuPont Dannike, italy probiotics and Swedish Probi. Lactobacillus plantarum powder (viable count is more than or equal to 1000 hundred million CFU/g).
Example 1
The present example provides a probiotic composition with improved insulin resistance and fasting glucose, formulated as shown in table 1 below:
table 1 probiotic composition formulation
Example 2
The present example provides a probiotic composition with improved insulin resistance and fasting glucose, formulated as shown in table 2 below:
table 2 probiotic composition formulation
Example 3
The present example provides a probiotic composition with improved insulin resistance and fasting glucose, formulated as shown in table 3 below:
table 3 probiotic composition formulation
Example 4
The present example provides a probiotic composition with improved insulin resistance and fasting glucose, formulated as shown in table 4 below:
table 4 probiotic composition formulation
Example 5
The present example provides a probiotic composition with improved insulin resistance and fasting glucose, formulated as shown in table 5 below:
table 5 probiotic composition formulation
Example 6
The present example provides a probiotic composition with improved insulin resistance and fasting glucose, formulated as shown in table 6 below:
TABLE 6 probiotic composition formulation
Example 7
The present example provides a probiotic composition with improved insulin resistance and fasting glucose, formulated as shown in table 7 below:
TABLE 7 probiotic composition formulation
Example 8
The present example provides a probiotic composition with improved insulin resistance and fasting glucose, formulated as shown in table 8 below:
table 8, probiotic composition formulation
Example 9
The present example provides a probiotic composition with improved insulin resistance and fasting glucose, formulated as shown in table 9 below:
table 9, probiotic composition formulation
Example 10
The present example provides a probiotic composition with improved insulin resistance and fasting glucose, formulated as shown in table 10 below:
table 10 probiotic composition formulation
Example 11
The present example provides a probiotic composition with improved insulin resistance and fasting glucose, formulated as shown in table 11 below:
table 11 probiotic composition formulation
Example 12
The present example provides a probiotic composition with improved insulin resistance and fasting glucose, formulated as shown in table 12 below:
table 12, probiotic composition formulation
Example 13
This example provides a method of preparing the probiotic composition of example 1 with improved insulin resistance and fasting glucose comprising the steps of:
(1) Weighing inulin and pumpkin powder according to the formula amount, uniformly mixing and marking as a material A;
(2) Weighing stachyose and partial resistant dextrin according to the formula amount, mixing uniformly, and calculating as material B for later use;
(3) Weighing fructo-oligosaccharide and silicon dioxide according to the formula amount for standby
(4) Weighing the rest part of resistant dextrin, and the formula amount of the Bifidobacterium lactis MN-Gup powder, the Lactobacillus acidophilus NCFM powder, the Bifidobacterium lactis B420 powder, the Bifidobacterium adolescentis BA02 powder and the Lactobacillus reuteri SD5865 powder, uniformly mixing and marking as a C material;
(5) And uniformly mixing the material A, the material B, the material C, fructo-oligosaccharide and silicon dioxide.
Example 14
The preparation method of the probiotic composition with the function of improving insulin resistance and fasting blood glucose of examples 2-5 and examples 8-12 is the same as that of example 13.
Example 15
This example provides a method of preparing the probiotic composition of example 6 with improved insulin resistance and fasting glucose comprising the steps of: weighing lactobacillus bifidus MN-Gup bacterial powder, lactobacillus acidophilus NCFM bacterial powder, lactobacillus bifidus B420 bacterial powder, bifidobacterium adolescentis BA02 bacterial powder, lactobacillus reuteri SD5865 bacterial powder and resistant dextrin according to the formula amount, and uniformly mixing.
Example 16
This example provides the same method of preparation of the probiotic composition of example 7 with improved insulin resistance and fasting glycemia as example 15.
Comparative example
The probiotic compositions of comparative examples 1-6 with improved insulin resistance and fasting glucose were formulated as follows in tables 13-14:
table 13 probiotic composition formulation
Table 14, probiotic composition formulation
The preparation method of the probiotic composition with improved insulin resistance and fasting blood glucose of comparative examples 1-6 is different from example 13 only in that in step (4), the remaining part of resistant dextrin and the formulation amount of bifidobacterium lactis MN-Gup powder, lactobacillus acidophilus NCFM powder, bifidobacterium lactis B420 powder, bifidobacterium adolescentis BA02 powder, lactobacillus reuteri SD5865 powder and/or lactobacillus plantarum powder are weighed and uniformly mixed and recorded as a material C.
Experimental example 1
1. And (3) test design:
the detection basis is as follows: an accessory 3 auxiliary blood sugar reducing function evaluation method for national food and medicine supervision [ 2012 ];
test animals:
SPF SD rats, 160+ -20 g, males, were adapted to the environment for 5 days after purchase, and normal animal hypoglycemic experiments were performed.
High heat energy feed: 10% of lard, 15% of sucrose, 15% of egg yolk powder, 5% of casein, 1.2% of cholesterol, 0.2% of sodium cholate, 0.6% of calcium bicarbonate, 0.4% of stone powder and 52.6% of mouse maintenance material.
Test article: the probiotic compositions of examples 1, 2, 6 and comparative examples 1-6 were formulated as shown in Table 14 below, and the test samples were administered to rats at a dose of 10ml/kg BW (wherein the test samples of example 2 and example 6 were each 2.68g in 10ml deionized water, and the test samples of the other groups were each 1.34g in 10ml deionized water)
Table 14 formulation of test article
Experimental grouping:
hypoglycemic model hypoglycemic experiment: test substances are respectively given to the set experiment groups, 1 blank control group and 1 model control group, deionized water is given to the model control group, and the experiment groups and the model control group are respectively given to the stomach according to 10 mL/kg.BW for continuous stomach infusion for 33d.
2. The experimental method comprises the following steps:
hyperglycemia model blood glucose reduction experiment (tetraoxypyrimidine induces insulin resistance glucose/lipid metabolism disorder model)
The molding method comprises the following steps: rats were fed with normal maintenance feed for 5d, fasted for 3-4h, tail blood was taken, and the blood glucose levels before glucose administration (i.e., 0 h) were measured, and the blood glucose levels after 2.5g/kg BW glucose administration were 0.5 and 2h as the base values for the animals in the batch. Blood glucose levels were grouped at 0h, 0.5h, i.e., blank, model, and experimental groups of 15 animals each. The blank control group was not treated, the experimental group was given the test sample, the model control group was given the same volume of deionized water, and 33d were continued. The groups were fed with maintenance feed, after 1 week the model control group and the experimental group were changed for high-heat feed, after 3 weeks of feeding, the model control group and the experimental group were fasted for 24 hours (without water inhibition), and were given a intraperitoneal injection of 103-105 mg/kg.BW of tetraoxypyrimidine with an injection amount of 1ml/100g body weight. The high heat energy feed is fed for 3-5 days after injection. At the end of the test, animals of each group were fasted for 3-4 hours and tested for fasting blood glucose, glucose tolerance, serum insulin and cholesterol, and triglyceride levels.
Test index-fasting blood glucose and glucose tolerance
Animals in each group were fasted for 3-4h, blood glucose values immediately before glucose administration (0 h) were measured for fasting blood glucose, probiotic compositions of different formulations and dosages were administered to test samples, model control groups were administered with the same volume of deionized water, blank control groups were not treated, glucose was orally administered for 15-20min to each group for 2.5 g/kg.BW, and blood glucose values of 0.5 and 2h were measured for each group after glucose administration.
Measurement index-cholesterol, triglyceride
Each group of animals is fasted for 3-4 hours, serum cholesterol and triglyceride are detected, if the serum cholesterol or triglyceride of the model control group is obviously increased, compared with the blank control group, the difference is obvious, and the establishment of the model lipid metabolism disorder is judged, and on the basis, the blood lipid change of the model control group and the tested sample group is observed.
Measurement index insulin
Animals in each group are fasted for 3-4 hours, serum insulin is detected, and compared with a blank control group, the insulin resistance index of the model control group is not obviously reduced. The insulin resistance of the model control group and the test sample group was observed.
Evaluation index: one of the two indexes of fasting blood glucose and glucose tolerance is positive, blood fat (total cholesterol and triglyceride) is not obviously increased, and the test result of the animal with the auxiliary blood glucose reducing function of the tested sample can be judged to be positive without influencing the fasting blood glucose of normal animals. The efficacy of the composition after dry prognosis was further evaluated.
3. Experimental results
(1) Fasting blood sugar
Results for fasting blood glucose as shown in table 15, example 2 group was 2-fold dose of example 1 group, which significantly reduced fasting blood glucose and was also significantly better than the example 1 group. From this, the probiotic composition of example 2 has a certain auxiliary hypoglycemic effect as a whole, and is a preferred formulation.
Table 15 pre-and post-experimental fasting glycemia in hyperglycemic model rats
* P <0.05 compared to model control, P <0.01 compared to model control.
(2) Triglyceride (TG)
The results of Triglyceride (TG) are shown in table 16 below, and example 2 group was 2-fold dose of example 1 group, which significantly reduced triglyceride levels and was also significantly better than the example 1 group. From this, the probiotic composition of example 2 has a certain triglyceride reducing effect as a whole, and is a preferable formulation.
TABLE 16 influence of post-experimental serum CHO, TG (X+ -SD) in hyperglycemic model rats
/>
* P <0.05 compared to model control, P <0.01 compared to model control.
(3) Insulin resistance
The results of insulin resistance are shown in table 17 below, and the probiotic composition of example 2 was able to significantly lower the insulin resistance index, and was also significantly better than the probiotic composition of example 1. From these results, the probiotic composition of example 2 had a certain improvement in insulin resistance and insulin sensitivity, and was favorable for improving blood glucose level.
TABLE 17 post-experimental insulin levels and insulin resistance index for hyperglycemia model rats
/>
* P <0.05 compared to model control, P <0.01 compared to model control.
It is apparent that the above examples are given by way of illustration only and are not limiting of the embodiments. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. While still being apparent from variations or modifications that may be made by those skilled in the art are within the scope of the invention.
Claims (8)
1. A probiotic composition for improving insulin resistance and fasting blood glucose, which is characterized by comprising a fungus powder mixture and food raw materials;
the fungus powder mixture consists of the following components in parts by weight:
1-50 parts of bifidobacterium animalis subspecies (Bifidobacterium animalis subsp.lactis) MN-Gup bacterial powder;
lactobacillus acidophilus (Lactobacillus acidophilus) NCFM powder 1-50 parts;
0.1-20 parts of bifidobacterium lactis (Bifidobacterium lactis) B420 bacteria powder;
1-50 parts of bifidobacterium adolescentis (Bifidobacterium adolescentis) BA02 bacteria powder; and
0.1-30 parts of lactobacillus reuteri (Lactobacillus ruteri) SD5865 bacteria powder;
the preservation number of the animal bifidobacterium subspecies (Bifidobacterium animalis subsp.lactis) MN-Gup is CGMCC No.15578;
the food material is at least one selected from stachyose, inulin, fructo-oligosaccharide, pumpkin powder and resistant dextrin.
2. The probiotic composition according to claim 1, further comprising a food or a medically acceptable adjuvant.
3. The probiotic composition according to claim 2, characterized in that the auxiliary material comprises silica.
4. A probiotic composition according to any one of claims 1 to 3, further comprising the following components in parts by weight:
stachyose, 0-100 parts;
inulin, 0-80 parts;
0-80 parts of fructo-oligosaccharide;
0-50 parts of pumpkin powder;
0-100 parts of resistant dextrin; and
silica, 0-10 parts.
5. A probiotic composition according to any one of claims 1 to 3, characterized by comprising the following components in parts by weight:
1-5 parts of bifidobacterium animalis milk subspecies MN-Gup bacterial powder;
1-5 parts of lactobacillus acidophilus NCFM powder;
0.5-2 parts of bifidobacterium lactis B420 powder;
1-5 parts of bifidobacterium adolescentis BA02 bacteria powder;
1-3 parts of lactobacillus reuteri SD5865 bacteria powder;
stachyose 30-60 parts;
30-60 parts of inulin;
10-30 parts of fructo-oligosaccharide;
10-20 parts of pumpkin powder;
30-80 parts of resistant dextrin; and
silica, 0.2-1 part.
6. A method of preparing a probiotic composition according to any one of claims 1 to 5, having an effect of improving insulin resistance and fasting glycemia, comprising weighing selected components in selected parts by weight and mixing them homogeneously.
7. The method of manufacturing according to claim 6, comprising:
weighing the selected food raw materials and auxiliary materials according to the selected weight portions, and uniformly mixing;
weighing all the bacterial powders according to the selected weight portions and uniformly mixing to obtain a bacterial powder mixture;
and uniformly mixing the mixture of the food raw materials and the auxiliary materials with the fungus powder mixture.
8. The method of manufacturing according to claim 7, comprising:
weighing inulin and pumpkin powder, uniformly mixing and marking as a material A;
weighing stachyose and mixing with part of resistant dextrin, and uniformly mixing to obtain material B;
respectively weighing fructo-oligosaccharide and silicon dioxide for later use;
weighing the rest of resistant dextrin, mixing with animal bifidobacterium milk subspecies MN-Gup, lactobacillus acidophilus NCFM, bifidobacterium lactis B420, bifidobacterium adolescentis BA02 and lactobacillus reuteri SD5865 powder, and marking the evenly mixed premix as a material C;
and uniformly mixing the material A, the material B, the material C, fructo-oligosaccharide and silicon dioxide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010911082.0A CN113197313B (en) | 2020-09-02 | 2020-09-02 | Probiotic composition with effects of improving insulin resistance and fasting blood glucose and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010911082.0A CN113197313B (en) | 2020-09-02 | 2020-09-02 | Probiotic composition with effects of improving insulin resistance and fasting blood glucose and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113197313A CN113197313A (en) | 2021-08-03 |
| CN113197313B true CN113197313B (en) | 2023-10-27 |
Family
ID=77025039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010911082.0A Active CN113197313B (en) | 2020-09-02 | 2020-09-02 | Probiotic composition with effects of improving insulin resistance and fasting blood glucose and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113197313B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113197288B (en) * | 2020-08-31 | 2023-05-09 | 内蒙古蒙牛乳业（集团）股份有限公司 | Probiotic composition for improving sugar tolerance and triglyceride level and preparation method thereof |
| CN115137757A (en) * | 2022-07-29 | 2022-10-04 | 承葛健康科技(广东)有限公司 | Probiotic composition assisting in reducing blood sugar |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102458415A (en) * | 2009-06-19 | 2012-05-16 | 丹尼斯科公司 | Bifidobacteria for treating diabetes and related conditions |
| CN106619743A (en) * | 2016-12-28 | 2017-05-10 | 山东龙力生物科技股份有限公司 | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink |
| CN109481510A (en) * | 2018-10-11 | 2019-03-19 | 张军毅 | It is a kind of to help to improve diabetes B and its synbiotic compound preparation of complication and preparation method thereof |
| CN109998113A (en) * | 2019-04-18 | 2019-07-12 | 广东省微生物研究所（广东省微生物分析检测中心） | A kind of functional food of the probiotics preparation with effect of lowering blood sugar |
| CN110354148A (en) * | 2019-08-19 | 2019-10-22 | 江南大学 | Bifidobacterium adolescentis CCFM1061 is preparing the application in functional microbial inoculum, food and/or drug |
| CN111346114A (en) * | 2018-12-21 | 2020-06-30 | 深圳市华大农业应用研究院 | Application of lactobacillus reuteri |
-
2020
- 2020-09-02 CN CN202010911082.0A patent/CN113197313B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102458415A (en) * | 2009-06-19 | 2012-05-16 | 丹尼斯科公司 | Bifidobacteria for treating diabetes and related conditions |
| CN104770739A (en) * | 2009-06-19 | 2015-07-15 | 杜邦营养生物科学有限公司 | Bifidobacteria for treating diabetes and related conditions |
| CN104784694A (en) * | 2009-06-19 | 2015-07-22 | 杜邦营养生物科学有限公司 | Bifidobacteria for treating diabetes and related conditions |
| CN106619743A (en) * | 2016-12-28 | 2017-05-10 | 山东龙力生物科技股份有限公司 | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink |
| CN109481510A (en) * | 2018-10-11 | 2019-03-19 | 张军毅 | It is a kind of to help to improve diabetes B and its synbiotic compound preparation of complication and preparation method thereof |
| CN111346114A (en) * | 2018-12-21 | 2020-06-30 | 深圳市华大农业应用研究院 | Application of lactobacillus reuteri |
| CN109998113A (en) * | 2019-04-18 | 2019-07-12 | 广东省微生物研究所（广东省微生物分析检测中心） | A kind of functional food of the probiotics preparation with effect of lowering blood sugar |
| CN111084385A (en) * | 2019-04-18 | 2020-05-01 | 广东省微生物研究所（广东省微生物分析检测中心） | Functional food of probiotic preparation with blood sugar reducing effect |
| CN110354148A (en) * | 2019-08-19 | 2019-10-22 | 江南大学 | Bifidobacterium adolescentis CCFM1061 is preparing the application in functional microbial inoculum, food and/or drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113197313A (en) | 2021-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110150669B (en) | Probiotic composition suitable for diabetic patients and application thereof | |
| US9737577B2 (en) | Lactic acid bacterium-containing preparation | |
| EP2546330A1 (en) | Lactic acid bacterium-containing preparation | |
| CN113197313B (en) | Probiotic composition with effects of improving insulin resistance and fasting blood glucose and preparation method thereof | |
| EP1794283A1 (en) | Metabolically active micro organisms and methods for their production | |
| Carreras et al. | Anti-obesity properties of the strain Bifidobacterium animalis subsp. lactis CECT 8145 in Zücker fatty rats | |
| CN113197921B (en) | Application of bifidobacterium lactis MN-Gup and microbial inoculum thereof in treating type 2 diabetes | |
| JP7267020B2 (en) | Fermented milk with inhibitory effect on blood sugar level elevation | |
| CN112210518A (en) | Lactobacillus reuteri and application thereof in reducing lipopolysaccharide concentration and improving insulin resistance | |
| WO2008012947A1 (en) | Anti-fatty liver agent | |
| CN116445346B (en) | Lactobacillus reuteri for improving polycystic ovary syndrome and application thereof | |
| TW201705969A (en) | Novel Lactobacillus mali APS1 and use thereof | |
| CN113197288B (en) | Probiotic composition for improving sugar tolerance and triglyceride level and preparation method thereof | |
| CN113207961B (en) | Bifidobacterium lactis MN-Gup dairy product and application thereof in improving type 2 diabetes | |
| CN112770749A (en) | Application of combination of bifidobacterium and berberine in treating pre-diabetes and type 2 diabetes | |
| KR102397916B1 (en) | A novel anaerobic microbe isolated from human milk and method of preventing or treating metabolic disease using thereof | |
| JP2022506081A (en) | Probiotic supplements for metabolic health containing Lactobacillus | |
| CN115466689B (en) | Probiotic composition for preventing and/or treating metabolic diseases and application thereof | |
| Chen et al. | Dietary soybeans worsen dextran sodium sulfate-induced colitis by disrupting intestinal ecology | |
| CN113207960B (en) | Bifidobacterium lactis MN-Gup fermented milk for improving obesity and preparation method thereof | |
| CN111448306A (en) | Anaerobic clavulanate (Anaerofuss stercoris) and application thereof | |
| CN111560335A (en) | Bifidobacterium lactis for relieving asthma and application thereof | |
| CN115025132B (en) | Synbiotic composition and preparation method and application thereof | |
| CN106974939B (en) | Application of probiotics of scleritis in treating and preventing obesity and related diseases | |
| CN106974940B (en) | Application of probiotics of scleritis in treating and preventing obesity and related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |